Resolution of depression: Antidepressant actions of resolvins
Major depressive disorder, one of the most widespread mental illnesses, brings about enormous individual and socioeconomic consequences. Conventional monoaminergic antidepressants require weeks to months to produce a therapeutic response, and approximately one-third of the patients fail to respond t...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Neuroscience Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0168010222002668 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087752259141632 |
|---|---|
| author | Satoshi Deyama Katsuyuki Kaneda Masabumi Minami |
| author_facet | Satoshi Deyama Katsuyuki Kaneda Masabumi Minami |
| author_sort | Satoshi Deyama |
| collection | DOAJ |
| description | Major depressive disorder, one of the most widespread mental illnesses, brings about enormous individual and socioeconomic consequences. Conventional monoaminergic antidepressants require weeks to months to produce a therapeutic response, and approximately one-third of the patients fail to respond to these drugs and are considered treatment-resistant. Although recent studies have demonstrated that ketamine, an N-methyl-D-aspartate receptor antagonist, produces rapid antidepressant effects in treatment-resistant patients, it also has undesirable side effects. Hence, rapid-acting antidepressants that have fewer adverse effects than ketamine are urgently required. D-series (RvD1–RvD6) and E-series (RvE1–RvE4) resolvins are endogenous lipid mediators derived from docosahexaenoic and eicosapentaenoic acids, respectively. These mediators reportedly play a pivotal role in the resolution of acute inflammation. In this review, we reveal that intracranial infusions of RvD1, RvD2, RvE1, RvE2, and RvE3 produce antidepressant-like effects in various rodent models of depression. Moreover, the behavioral effects of RvD1, RvD2, and RvE1 are mediated by the activation of the mechanistic target of rapamycin complex 1, which is essential for the antidepressant-like actions of ketamine. Finally, we briefly provide our perspective on the possible role of endogenous resolvins in stress resilience. |
| format | Article |
| id | doaj-art-74e799bca9f945db832a869dcc633e40 |
| institution | Kabale University |
| issn | 0168-0102 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neuroscience Research |
| spelling | doaj-art-74e799bca9f945db832a869dcc633e402025-02-06T05:10:59ZengElsevierNeuroscience Research0168-01022025-02-012118592Resolution of depression: Antidepressant actions of resolvinsSatoshi Deyama0Katsuyuki Kaneda1Masabumi Minami2Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920–1192, Japan; Correspondence to: Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920–1192, Japan.Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920–1192, JapanDepartment of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060–0812, JapanMajor depressive disorder, one of the most widespread mental illnesses, brings about enormous individual and socioeconomic consequences. Conventional monoaminergic antidepressants require weeks to months to produce a therapeutic response, and approximately one-third of the patients fail to respond to these drugs and are considered treatment-resistant. Although recent studies have demonstrated that ketamine, an N-methyl-D-aspartate receptor antagonist, produces rapid antidepressant effects in treatment-resistant patients, it also has undesirable side effects. Hence, rapid-acting antidepressants that have fewer adverse effects than ketamine are urgently required. D-series (RvD1–RvD6) and E-series (RvE1–RvE4) resolvins are endogenous lipid mediators derived from docosahexaenoic and eicosapentaenoic acids, respectively. These mediators reportedly play a pivotal role in the resolution of acute inflammation. In this review, we reveal that intracranial infusions of RvD1, RvD2, RvE1, RvE2, and RvE3 produce antidepressant-like effects in various rodent models of depression. Moreover, the behavioral effects of RvD1, RvD2, and RvE1 are mediated by the activation of the mechanistic target of rapamycin complex 1, which is essential for the antidepressant-like actions of ketamine. Finally, we briefly provide our perspective on the possible role of endogenous resolvins in stress resilience.http://www.sciencedirect.com/science/article/pii/S0168010222002668AntidepressantDepressionHippocampusMechanistic target of rapamycin complex 1Medial prefrontal cortexResolvin |
| spellingShingle | Satoshi Deyama Katsuyuki Kaneda Masabumi Minami Resolution of depression: Antidepressant actions of resolvins Neuroscience Research Antidepressant Depression Hippocampus Mechanistic target of rapamycin complex 1 Medial prefrontal cortex Resolvin |
| title | Resolution of depression: Antidepressant actions of resolvins |
| title_full | Resolution of depression: Antidepressant actions of resolvins |
| title_fullStr | Resolution of depression: Antidepressant actions of resolvins |
| title_full_unstemmed | Resolution of depression: Antidepressant actions of resolvins |
| title_short | Resolution of depression: Antidepressant actions of resolvins |
| title_sort | resolution of depression antidepressant actions of resolvins |
| topic | Antidepressant Depression Hippocampus Mechanistic target of rapamycin complex 1 Medial prefrontal cortex Resolvin |
| url | http://www.sciencedirect.com/science/article/pii/S0168010222002668 |
| work_keys_str_mv | AT satoshideyama resolutionofdepressionantidepressantactionsofresolvins AT katsuyukikaneda resolutionofdepressionantidepressantactionsofresolvins AT masabumiminami resolutionofdepressionantidepressantactionsofresolvins |